NCT04940052 2025-12-02Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid CancerNovartisPhase 3 Active not recruiting153 enrolled
NCT02034110 2023-08-21Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare CancersNovartisPhase 2 Completed206 enrolled 40 charts 2 FDA
NCT02538627 2017-09-05Phase 1 Combination Study of MM-151 With MM-121, MM-141, or TrametinibMerrimack PharmaceuticalsPhase 1 Terminated5 enrolled